Side Effects
Epithalon's safety profile appears favorable based on the available data, though this data is limited and originates predominantly from a single research group.
Commonly Reported:
- Injection site reactions: mild redness, swelling, or irritation at the injection site (consistent with most subcutaneous peptide injections)
- Drowsiness or fatigue: likely related to melatonin modulation, particularly with evening dosing
- Mild headache: reported infrequently and typically transient
Rarely Reported:
- Gastrointestinal upset
- Allergic reactions (no severe cases documented in published research)
Serious Adverse Events: No serious adverse events have been reported in published studies. Long-term observational studies spanning up to 15 years in elderly patients did not document significant adverse effects, though these studies were not designed as formal safety trials.
Theoretical Concerns:
- Telomerase and cancer risk: Telomerase reactivation is a hallmark of most cancers, and any compound that activates telomerase raises legitimate questions about potential tumor promotion. The 2025 study demonstrating ALT pathway activation in cancer cell lines adds to this concern. While animal studies from Khavinson's group actually showed reduced tumor incidence with Epithalon treatment, individuals with active or undetected malignancies should exercise particular caution.
- Immunogenicity: The FDA has identified Epithalon among peptides that may pose immunogenicity risks, the potential for the body to mount an immune response against the peptide itself.
Sourcing Risks: Epithalon sourced from unregulated research chemical suppliers carries inherent risks of contamination, incorrect dosing, and unknown impurity profiles that are separate from the compound's intrinsic safety characteristics. Independent third-party testing is advisable for any research peptide.